Proteomic and Metabolomic Analysis of PCK2 in Group 3 Medulloblastoma Cells

A 1.4 MB dataset containing proteomic and metabolomic measurements from Group 3 medulloblastoma cell lines. It was created by Medha Gayathri J Pai and last updated on May 6, 2026. The data explores metabolic alterations following PCK2 knockdown in this aggressive pediatric brain tumor subtype.

Use Cases

• Identify metabolic vulnerabilities for therapeutic targeting based on dysregulated metabolic interactors.
• Investigate the role of PCK2 in metabolic flexibility under nutrient stress in cancer cells.
• Analyze the relationship between ribosomal/RNA processing pathways and oncogenic metabolism.
• Explore redox imbalance in cancer cells based on alterations in phosphocholine and carnitine metabolites.

Strengths

• Data is derived from two independent patient datasets, suggesting validation.
• Combines quantitative proteomics and complementary metabolomic profiling for a multi-omics view.
• Focuses on Group 3 medulloblastoma, which accounts for 20–25% of cases and has a poor prognosis.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect bias inherent to the specific cell lines (HD-MB03 and G3MB) studied.

Provenance

Source

figshare

Collection Method

Proteomic analysis via Evosep-Tims TOF and complementary metabolomic profiling following shRNA-mediated knockdown of PCK2.

Freshness

Last updated 2026-05-06 05:14:39